Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, Belfiore A: A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab. 2002, 87: 245-254. 10.1210/jc.87.1.245.
Dimitriadis G, Parry-Billings M, Bevan S, Dunger DB, Piva T, Krause U, Wegener G, Newsholme E: Effects of insulin-like growth factor-I on the rates of glucose transport and utilisation in rat skeletal muscle in vitro. Biochem J. 1992, 285: 269-274.
Le Roith D, Bondy C, Yakar S, Liu JL, Butler A: The somatomedin hypothesis: 2001. Endocr Rev. 2001, 22: 53-74. 10.1210/er.22.1.53.
Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995, 16: 3-34. 10.1210/er.16.1.3.
Clemmons DR, Cascieri MA, Camacho-Hubner C, McCusker RH, Bayne ML: Discrete alterations of the insulin-like growth factor I molecule which alter its affinity for insulin-like growth factor-binding proteins result in changes in bioactivity. J Biol Chem. 1990, 265: 12210-12216.
Gallego MI, Binart N, Robinson GW, Okagaki R, Coschigano KT, Perry J, Kopchick JJ, Oka T, Kelly PA, Henninghausen L: Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. Dev Biol. 2001, 229: 163-175. 10.1006/dbio.2000.9961.
Ruan W, Newman CB, Kleinberg DL: Intact and amino-terminally shortened forms of insulin-like growth factor-I induce mammary gland differentiation and development. Proc Natl Acad Sci USA. 1992, 89: 10872-10876.
Walden PD, Ruan W, Feldman M, Kleinberg DL: Evidence that the mammary fat pad mediates the action of growth hormone in mammary gland development. Endocrinology. 1998, 139: 659-662. 10.1210/en.139.2.659.
Ruan W, Kleinberg DL: Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology. 1999, 140: 5075-5081. 10.1210/en.140.11.5075.
Forsyth IA, Gabai G, Morgan G: Spatial and temporal expression of insulin-like growth factor-I, insulin-like growth factor-II and the insulin-like growth factor-I receptor in the sheep fetal mammary gland. J Dairy Res. 1999, 66: 35-44. 10.1017/S0022029998003240.
Hovey RC, MacKenzie DD, McFadden TB: The proliferation of mouse mammary epithelial cells in response to specific mitogens is modulated by the mammary fat pad in vitro. In Vitro Cell Dev Biol Anim. 1998, 34: 385-392.
Smith PJ, Wise LS, Berkowitz R, Wan C, Rubin CS: Insulin-like growth factor-I is an essential regulator of the differentiation of 3T3-L1 adipocytes. J Biol Chem. 1988, 263: 9402-9408.
Richert MM, Wood TL: The insulin-like growth factors (IGF) and IGF type I receptor during postnatal growth of the murine mammary gland: sites of messenger ribonucleic acid expression and potential functions. Endocrinology. 1999, 140: 454-461. 10.1210/en.140.1.454.
Clarke RB, Howell A, Anderson E: Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br J Cancer. 1997, 75: 251-257.
Clarke RB, Howell A, Potten CS, Anderson E: Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 1997, 57: 4987-4991.
Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, Karin M: IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell. 2001, 107: 763-775. 10.1016/S0092-8674(01)00599-2.
LeRoith D: Insulin-like growth factor I receptor signaling – overlapping or redundant pathways?. Endocrinology. 2000, 141: 1287-1288. 10.1210/en.141.4.1287.
Le Roith D: Regulation of proliferation and apoptosis by the insulin-like growth factor I receptor. Growth Horm IGF Res. 2000, 10A: S12-S13.
Zimmermann S, Moelling K: Phosphorylation and regulation of Raf by Akt (protein kinase B). Science. 1999, 286: 1741-1744. 10.1126/science.286.5445.1741.
Deeks S, Richards J, Nandi S: Maintenance of normal rat mammary epithelial cells by insulin and insulin-like growth factor 1. Exp Cell Res. 1988, 174: 448-460.
Shamay A, Cohen N, Niwa M, Gertler A: Effect of insulin-like growth factor I on deoxyribonucleic acid synthesis and galactopoiesis in bovine undifferentiated and lactating mammary tissue in vitro. Endocrinology. 1988, 123: 804-809.
Bonette SG, Hadsell DL: Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology. 2001, 142: 4937-4945. 10.1210/en.142.11.4937.
Gilmore AP, Valentijn A, Wang P, Ranger AM, Bundred N, O'Hare MJ, Wakeling A, Korsmeyer SJ, Streuli CH: Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin like growth factor receptor. J Biol Chem. 2002, 277: 27643-27650. 10.1074/jbc.M108863200.
Farrelly N, Lee Y-J, Oliver J, Dive C, Streuli CH: Extracellular matrix regulates apoptosis in mammary epithelium through a control on insulin signaling. J Cell Biol. 1999, 144: 1337-1348. 10.1083/jcb.144.6.1337.
Strange R, Li F, Saurer S, Burkhardt A, Friis RR: Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development. 1992, 115: 49-58.
Metcalfe AD, Gilmore AP, Klinowska T, Oliver J, Valentijn AJ, Brown R, Ross A, MacGregor G, Hickman JA, Streuli CH: Developmental regulation of Bcl-2 family protein expression in the involuting mammary gland. J Cell Sci. 1999, 112: 1771-1783.
Prince JM, Klinowska T, Marshman E, Lowe ET, Mayer U, Miner J, Aberdam D, Vestweber D, Gusterson B, Streuli CH: Cell–matrix interactions during development and apoptosis of the mouse mammary gland in vivo. Dev Dyn. 2002, 223: 497-516. 10.1002/dvdy.10070.
Neuenschwander S, Schwartz A, Wood TL, Roberts CT, Henninghausen L, LeRoith D: Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest. 1996, 97: 2225-2232.
Hadsell DL, Greenberg JM, Fligger CR, Baumrucker CR, Rosen CJ: Targeted expression of des(1–3) human insulin growth factor 1 in transgenic mice influences mammary gland development and IGF binding protein expression. Endocrinology. 1996, 137: 321-330. 10.1210/en.137.1.321.
Moorehead RA, Fata JE, Johnson MB, Khokha R: Inhibition of mammary epithelial apoptosis and sustained phosphorylation of Akt/PKB in MMTV-IGF-II transgenic mice. Cell Death Differ. 2001, 8: 16-29. 10.1038/sj.cdd.4400762.
Schwertfeger KL, Richert MM, Anderson SM: Mammary gland involution is delayed by activated Akt in transgenic mice. Mol Endocrinol. 2001, 15: 867-881. 10.1210/me.15.6.867.
Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ: Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol. 2001, 21: 2203-2212. 10.1128/MCB.21.6.2203-2212.2001.
Ruan W, Catanese V, Wieczorak R, Feldman M, Kleinberg DL: Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology. 1995, 136: 1296-1302. 10.1210/en.136.3.1296.
Richards RG, DiAugustine RP, Petrusz P, Clark GC, Sebastian J: Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus. Proc Natl Acad Sci USA. 1996, 93: 12002-12007. 10.1073/pnas.93.21.12002.
Klotz DM, Hewitt SC, Ciana P, Raviscioni M, Lindzey JK, Foley J, Maggi A, DiAugustine RP, Korach KS: Requirement of estrogen receptor-alpha in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J Biol Chem. 2002, 277: 8531-8537. 10.1074/jbc.M109592200.
Stull MA, Richert MM, Loladze AV, Wood TL: Requirement for IGF-I in epidermal growth factor-mediated cell cycle progression of mammary epithelial cells. Endocrinology. 2002, 143: 1872-1879. 10.1210/en.143.5.1872.
Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A: EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 1999, 402: 884-888.
Moro L, Venturino M, Bozzo C, Silengo L, Altruda F, Beguinot L, Tarone G, Defilippi P: Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival. EMBO J. 1998, 17: 6622-6632. 10.1093/emboj/17.22.6622.
Roskelley CD, Srebrow A, Bissell MJ: A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression. Curr Opin Cell Biol. 1995, 7: 736-747. 10.1016/0955-0674(95)80117-0.
Streuli CH, Edwards GM: Control of normal mammary epithelial phenotype by integrins. J Mamm Gland Biol Neoplasia. 1998, 3: 151-163. 10.1023/A:1018742822565.
Miranti CK, Brugge JS: Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol. 2002, 4: E83-E90. 10.1038/ncb0402-e83.
Vuori K, Ruoslahti E: Association of insulin receptor substrate-1 with integrins. Science. 1994, 266: 1576-1578.
Lee Y-J, Streuli CH: Extracellular matrix selectively modulates the response of mammary epithelial cells to different soluble signaling ligands. J Biol Chem. 1999, 274: 22401-22408. 10.1074/jbc.274.32.22401.
Woodward TL, Xie J, Fendrick JL, Haslam SZ: Proliferation of mouse mammary epithelial cells in vitro: interactions among epidermal growth factor, insulin-like growth factor I, ovarian hormones, and extracellular matrix proteins. Endocrinology. 2000, 141: 3578-3586. 10.1210/en.141.10.3578.
Shaw LM: Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol Cell Biol. 2001, 21: 5082-5093. 10.1128/MCB.21.15.5082-5093.2001.
Wood TL, Richert MM, Stull MA, Allar MA: The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. J Mammary Gland Biol Neoplasia. 2000, 5: 31-42. 10.1023/A:1009511131541.
Tonner E, Barber MC, Travers MT, Logan A, Flint DJ: Hormonal control of insulin-like growth factor binding protein-5 production in the involuting mammary gland of the rat. Endocrinology. 1997, 138: 5101-5107. 10.1210/en.138.12.5101.
Chapman RS, Duff EK, Lourenco PC, Tonner E, Flint DJ, Clarke AR, Watson CJ: A novel role for IRF-1 as a suppressor of apoptosis. Oncogene. 2000, 19: 6386-6391. 10.1038/sj.onc.1204016.
Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K, Akira S, Clarke AR, Watson CJ: Suppression of epithelial apoptosis and delayed mammary gland involution. Genes Dev. 1999, 13: 2604-2616. 10.1101/gad.13.19.2604.
Nguyen AV, Pollard JW: Transforming growth factor beta3 induces cell death during the first stage of mammary gland involution. Development. 2000, 127: 3107-3118.
Fata JE, Leco KJ, Voura EB, Yu HY, Waterhouse P, Murphy G, Moorehead RA, Khokha R: Accelerated apoptosis in the Timp-3-deficient mammary gland. J Clin Invest. 2001, 108: 831-841. 10.1172/JCI200113171.
Eriksson U, Duc G, Froesch ER, Zapf J: Insulin-like growth factors (IGF) I and II and IGF binding proteins (IGFBPs) in human colostrum/transitory milk during the first week post-partum: comparison with neonatal and maternal serum. Biochem Biophys Res Commun. 1993, 196: 267-273. 10.1006/bbrc.1993.2244.
Breier BH, Milsom SR, Blum WF, Schwander J, Gallaher BL, Gluckman PD: Insulin-like growth factors and their binding proteins in plasma and milk after hormone-stimulated galactopoiesis in normally lactating women. Acta Endocrinol Copenh. 1993, 129: 427-435.
Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly JM: Differential IGF-independent effects of insulin-like growth factor binding proteins (1–6) on apoptosis of breast epithelial cells. J Cell Biochem. 1999, 75: 652-664. 10.1002/(SICI)1097-4644(19991215)75:4<652::AID-JCB11>3.0.CO;2-0.
Ricort J-M, Binoux M: Insulin-like growth factor (IGF) binding protein-3 inhibits type I IGF receptor activation independently of its IGF binding affinity. Endocrinology. 2001, 142: 108-113. 10.1210/en.142.1.108.
Nickerson T, Huynh H, Pollak M: Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun. 1997, 237: 690-693. 10.1006/bbrc.1997.7089.
Oh Y, Muller H, Pham H, Rosenfeld RG: Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem. 1993, 268: 26045-26058.
Leal SM, Huang SS, Huang JS: Interactions of high affinity insulin-like growth factor binding proteins with the type V transforming-receptor in mink lung epithelial cells. J Biol Chem. 1999, 274: 6711-6717. 10.1074/jbc.274.10.6711.
Schedlich LJ, Young TF, Firth SM, Baxter RC: Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem. 2000, 29: 18347-18352.
Jones JI, Gockerman A, Busby WH, Camacho-Hubner C, Clemmons DR: Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol. 1993, 121: 679-687.
Parker A, Clarke JB, Busby WH, Clemmons DR: Identification of the extracellular matrix binding sites for insulin-like growth factor binding protein-5. J Biol Chem. 1996, 271: 13523-13529. 10.1074/jbc.271.23.13523.
Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG: Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab. 1992, 75: 1046-1053. 10.1210/jc.75.4.1046.
Collett-Solberg PF, Cohen P: The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am. 1996, 25: 591-614.
Nam TJ, Busby WH, Clemmons DR: Human fibroblasts secrete a serine protease that cleaves insulin-like growth factor-binding protein-5. Endocrinology. 1994, 135: 1385-1391. 10.1210/en.135.4.1385.
Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM: ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun. 2000, 278: 511-515. 10.1006/bbrc.2000.3835.
Lalou C, Silve C, Rosato R, Segovia B, Binoux M: Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. Endocrinology. 1994, 135: 2318-2326. 10.1210/en.135.6.2318.
Zheng B, Clarke JB, Busby WHJ, Duan C, Clemmons DR: Insulin-like growth factor-binding protein-5 is cleaved by physiological concentrations of thrombin. Endocrinology. 1998, 139: 1708-1714. 10.1210/en.139.4.1708.
Overgaard MT, Boldt HB, Laursen LS, Sottrup-Jensen L, Conover CA, Oxvig C: Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. J Biol Chem. 2001, 276: 21849-21853. 10.1074/jbc.M102191200.
Talhouk RS, Bissell MJ, Werb Z: Coordinated expression of extracellular matrix-degrading proteinases and their inhibitors regulates mammary epithelial function during involution. J Cell Biol. 1992, 118: 1271-1282.
Werner H, LeRoith D: The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncogene. 1997, 8: 71-92.
Paik S: Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat. 1992, 22: 31-38.
Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N: Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol. 1989, 3: 509-517.
Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V: Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res. 1993, 53: 3736-3740.
Resnik JL, Reichart DB, Huey K, Webster NJ, Seely B: Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res. 1998, 58: 1159-1164.
Zhang X, Yee D: Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res. 2000, 2: 170-175. 10.1186/bcr50.
Pollak M: Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat. 1998, 47: 209-217. 10.1023/A:1005950916707.
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollack M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998, 351: 1393-1396. 10.1016/S0140-6736(97)10384-1.
Bhatavdekar JM, Patel DD, Karelia NH, Vora HH, Ghosh N, Shah NG, Balar DB, Trivedi SN: Tumor markers in patients with advanced breast cancer as prognosticators: a preliminary study. Breast Cancer Res Treat. 1994, 30: 293-297.
Bruning PF, Van Doorn J, Bonfrer JM, Van Noord PA, Korse CM, Linders TC, Hart AA: Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer. 1995, 62: 266-270.
Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS: Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology. 1998, 9: 570-573.
Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D: Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst. 1996, 88: 601-606.
Stewart AJ, Johnson MD, May FE, Westley BR: Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem. 1990, 265: 21172-21178.
Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osbourne CK, Yee D: Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999, 13: 787-796. 10.1210/me.13.5.787.
Lee AV, Darbre P, King RJ: Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. Mol Cell Endocrinol. 1994, 99: 211-220. 10.1016/0303-7207(94)90010-8.
Clemmons DR, Camacho HC, Coronado E, Osbourne CK: Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology. 1990, 127: 2679-2686.
Karey KP, Sirbasku DA: Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res. 1988, 48: 4083-4092.
Figueroa JA, Sharma J, Jackson JG, McDermott MJ, Hilsenbeck SG, Yee D: Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum and estrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Physiol. 1993, 157: 229-236.
McGuire SE, Hilsenbeck SG, Figueroa JA, Jackson JG, Yee D: Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Lett. 1994, 77: 25-32. 10.1016/0304-3835(94)90343-3.
Mathieu M, Vignon F, Capony F, Rochefort H: Estradiol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: a receptor saturation mechanism to increase the secretion of lysosomal proenzymes. Mol Endocrinol. 1991, 5: 815-822.
Pollak M, Blouin MJ, Zhang JC, Kopchick JJ: Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer. 2001, 85: 428-430. 10.1054/bjoc.2001.1895.
Szepeshazi K, Schally AV, Armatis P, Groot K, Hebert F, Feil A, Varga JL, Halmos G: Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth. Endocrinology. 2001, 142: 4371-4378. 10.1210/en.142.10.4371.
Friend F: Cancer and the potential place for growth hormone receptor antagonist therapy. Growth Horm IGF Res. 2001, 11: S121-S123.
Chan TW, Pollak M, Huynh H: Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure anti-estrogen ICI 182,780. Clin Cancer Res. 2001, 7: 2545-2554.